Can Wegovy Pill’s Rapid Uptake Give Novo Nordisk an Edge Over LLY?
Novo Nordisk NVO remains one of the dominant players in the rapidly expanding obesity treatment market. The company markets…
Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, June 7, 2026 /PRNewswire/ — Novo Nordisk today announced Wegovy® (semaglutide) tablets 25…